COSCIENS Biopharma Inc., listed on the Toronto Stock Exchange as CSCI and on the OTCQB as CSCIF, announced on October 19, 2026, the release of a new corporate presentation. This presentation is now accessible on the company’s official website and is intended to offer a comprehensive overview of COSCIENS and its subsidiary operations. One significant highlight is the recent acquisition of Nualtis, which has expanded COSCIENS' portfolio and aligns with its strategic growth objectives.
Additionally, COSCIENS provided updates regarding its ongoing convertible debenture offering. This move aims to enhance its capital structure and support future initiatives as the company positions itself in the biopharmaceutical sector. Investors and interested parties can review the presentation and further information on the company's website at www.cosciensbio.com. Available materials are designed to assist stakeholders in understanding COSCIENS' vision and operational strategy moving forward.
Analyzed Canadian Outlets (1)
1 headline